Nurix Therapeutics, Inc.
HealthcareNASDAQ:NRIX · NASDAQ Global Market
-$0.03 today
Vol 2.56M · Avg 1.50M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-49.1%
avg -25.4%
ROIC
-47.3%
avg -48.8%
ROA
-38.4%
avg -32.1%
Analysis
ROA is currently the strongest return metric at -38.4% versus its period average of -32.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Arthur T. Sands | Chief Executive Officer, President & Director | $1.21M | — | 64 | $562,500.00 | 0.65% |
Gwenn Hansen | Chief Scientific Officer | $866,275.00 | — | 55 | $123,613.00 | 0.14% |
Johannes Van Houte | Chief Financial Officer | $848,254.00 | — | 59 | $38,174.00 | 0.04% |
Christine Ring | Chief Legal Officer, Secretary & Chief Compliance Officer | $815,088.00 | — | 61 | $13,579.00 | 0.02% |
Arthur Weiss | Founder & Member of Scientific Advisory Board | — | — | — | $562,500.00 | 0.65% |
John Kuriyan | Founder & Member of Scientific Advisory Board | — | — | — | — | — |
Jason Kantor | Chief Business Officer | — | — | — | — | — |
Pasit Phiasivongsa | Chief Technical Officer | — | — | — | — | — |
Christopher Phelps | Senior Vice President & Head of Early Drug Discovery | — | — | — | — | — |
Rita Kwong | Senior Accounting Manager | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
29
$2.65M
Net Sentiment
$2.65M
Net selling
Most Active
Ring Christine
15 transactions
1–10 of 29
Analysis
Insiders reported 0 buys worth $0.00 and 29 sells worth $2.65M over the last 12 months. That adds up to net selling of $2.65M. Ring Christine was the most active insider with 15 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | +7.5% | +36.4% (8yr)10 analysts |
| Net Income | N/A | N/A | N/A | N/A10 analysts |
| EBIT | N/A | N/A | N/A | N/A10 analysts |
Analysis
Recent growth has been strongest in Revenue at +7.5% over three years. Forward estimates point to Revenue at +36.4% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Tango Therapeutics, Inc.
NASDAQ:TNGX
$3.59B
Kodiak Sciences Inc.
NASDAQ:KOD
$1.80B
Septerna, Inc.
NASDAQ:SEPN
$1.62B
Fortrea Holdings Inc.
NASDAQ:FTRE
$1.56B
UroGen Pharma Ltd.
NASDAQ:URGN
$1.45B
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
$1.09B
Xencor, Inc.
NASDAQ:XNCR
$914.17M
Phathom Pharmaceuticals, Inc.
NASDAQ:PHAT
$827.07M
Kura Oncology, Inc.
NASDAQ:KURA
$803.41M
BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOT
$620.83M
Who manages NRIX?
Nurix Therapeutics, Inc. (NRIX) lists 10 active executives. The top listed executive is Arthur Weiss, Founder & Member of Scientific Advisory Board.
Are NRIX insiders buying or selling?
Recent insider activity shows net buying of $29.54M.
Explore More
Continue the stock analysis
Jump to another research area for this company.